Acadian Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $65.5M | Sell |
818,164
-107,959
| -12% | -$8.9M | 0.09% | 188 |
|
|
2025
Q4 | $78.9M | Buy |
926,123
+73,870
| +9% | +$6.06M | 0.13% | 152 |
|
|
2025
Q3 | $66.3M | Buy |
852,253
+401,257
| +89% | +$31.4M | 0.12% | 163 |
|
|
2025
Q2 | $35.3M | Buy |
450,996
+316,977
| +237% | +$23.6M | 0.07% | 220 |
|
|
2025
Q1 | $9.71M | Buy |
134,019
+88,099
| +192% | +$6.31M | 0.03% | 341 |
|
|
2024
Q4 | $3.4M | Buy |
45,920
+1,487
| +3% | +$104K | 0.01% | 630 |
|
|
2024
Q3 | $2.93M | Sell |
44,433
-44,370
| -50% | -$3.22M | 0.01% | 641 |
|
|
2024
Q2 | $8.2M | Buy |
88,803
+72,458
| +443% | +$6.42M | 0.03% | 390 |
|
|
2024
Q1 | $1.56M | Sell |
16,345
-24,197
| -60% | -$2.03M | 0.01% | 723 |
|
|
2023
Q4 | $3.09M | Buy |
40,542
+26,977
| +199% | +$1.88M | 0.01% | 572 |
|
|
2023
Q3 | $938K | Sell |
13,565
-18,729
| -58% | -$1.51M | ﹤0.01% | 866 |
|
|
2023
Q2 | $3.04M | Sell |
32,294
-26,055
| -45% | -$2.26M | 0.01% | 583 |
|
|
2023
Q1 | $4.82M | Sell |
58,349
-281,686
| -83% | -$22.1M | 0.02% | 464 |
|
|
2022
Q4 | $25.4M | Buy |
340,035
+313,236
| +1,169% | +$24.1M | 0.12% | 176 |
|
|
2022
Q3 | $2.21M | Sell |
26,799
-3,213
| -11% | -$309K | 0.01% | 609 |
|
|
2022
Q2 | $2.85M | Buy |
30,012
+2,303
| +8% | +$238K | 0.01% | 542 |
|
|
2022
Q1 | $3.26M | Sell |
27,709
-864
| -3% | -$96.9K | 0.01% | 555 |
|
|
2021
Q4 | $3.7M | Sell |
28,573
-164,046
| -85% | -$19.1M | 0.01% | 528 |
|
|
2021
Q3 | $21.8M | Buy |
192,619
+179,721
| +1,393% | +$20.5M | 0.08% | 201 |
|
|
2021
Q2 | $1.34M | Sell |
12,898
-813
| -6% | -$76.6K | 0.01% | 828 |
|
|
2021
Q1 | $1.15M | Buy |
13,711
+4,626
| +51% | +$391K | ﹤0.01% | 905 |
|
|
2020
Q4 | $829K | Sell |
9,085
-3,318
| -27% | -$275K | ﹤0.01% | 1047 |
|
|
2020
Q3 | $990K | Sell |
12,403
-78,539
| -86% | -$6.13M | ﹤0.01% | 918 |
|
|
2020
Q2 | $6.29M | Buy |
+90,942
| New | +$6.46M | 0.03% | 438 |
|
|
2019
Q4 | – | Sell |
-9,690
| Closed | -$710K | – | 1952 |
|
|
2019
Q3 | $710K | Buy |
+9,690
| New | +$681K | ﹤0.01% | 995 |
|
|
2019
Q2 | – | Sell |
-7,410
| Closed | -$473K | – | 1880 |
|
|
2019
Q1 | $473K | Buy |
7,410
+4,638
| +167% | +$265K | ﹤0.01% | 1113 |
|
|
2018
Q4 | $142K | Buy |
+2,772
| New | +$140K | ﹤0.01% | 1191 |
|
|
2016
Q3 | – | Sell |
-22,197
| Closed | -$737K | – | 1463 |
|
|
2016
Q2 | $737K | Buy |
+22,197
| New | +$759K | ﹤0.01% | 691 |
|
|
2015
Q3 | – | Sell |
-3,984
| Closed | -$95K | – | 1334 |
|
|
2015
Q2 | $95K | Sell |
3,984
-32,100
| -89% | -$724K | ﹤0.01% | 1021 |
|
|
2015
Q1 | $858K | Sell |
36,084
-314,268
| -90% | -$7.05M | ﹤0.01% | 678 |
|
|
2014
Q4 | $7.44M | Buy |
350,352
+335,910
| +2,326% | +$6.75M | 0.03% | 334 |
|
|
2014
Q3 | $246K | Buy |
+14,442
| New | +$228K | ﹤0.01% | 751 |
|
Other funds holding EW
VCM
VPM
Acadian Asset Management's EW Position: Q1 2026 in Review
Acadian Asset Management reduced its Edwards Lifesciences (EW) stake by 12% in Q1 2026, selling an estimated $8.9M and leaving 818,164 shares worth $65.5M. The position accounts for 0.09% of the portfolio, ranked #188.
Acadian Asset Management first reported a position in EW in Q3 2014 and has held it in 32 quarters since. The position peaked at $78.9M in Q4 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Acadian Asset Management held 818,164 shares of Edwards Lifesciences worth $65.5M as of Q1 2026.
- Acadian Asset Management sold 107,959 Edwards Lifesciences shares in Q1 2026, an estimated $8.9M.
- Edwards Lifesciences made up 0.09% of Acadian Asset Management's portfolio in Q1 2026, its #188 holding.
- Acadian Asset Management first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 32 quarters since.
- Acadian Asset Management's Edwards Lifesciences position peaked at $78.9M in Q4 2025.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.